| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Skye Bioscience, Inc.
13D/A
SKYE · 83086J309
|
26.1% |
9/24/2026
Event 9/22/2026
|
||||
| 5AM Partners VII, LLC | 25.7% | |||||
| 5AM Ventures VII, L.P. | 25.7% | |||||
| 5AM Partners II, LLC | 0% | |||||
| 5AM Ventures II, L.P. | 0% | |||||
| 5AM Co-Investors II, L.P. | 0% | |||||
| Andrew J. Schwab | 26.1% | |||||
| Kush Parmar | 25.7% | |||||
| John D. Diekman | 0% | |||||
| Scott M. Rocklage | 0% | |||||
|
Skye Bioscience, Inc.
13D/A
SKYE · 83086J200
|
30.2% |
8/18/2026
Event 8/14/2026
|
||||
| 5AM Partners VII, LLC | 25.9% | |||||
| 5AM Ventures VII, L.P. | 25.9% | |||||
| 5AM Partners II, LLC | 4.1% | |||||
| 5AM Ventures II, L.P. | 4.0% | |||||
| 5AM Co-Investors II, L.P. | 0.2% | |||||
| Andrew J. Schwab | 30.2% | |||||
| Kush Parmar | 25.9% | |||||
| John D. Diekman | 4.1% | |||||
| Scott M. Rocklage | 4.1% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Surrozen, Inc.
13G/A
SRZN · 86889P208
|
7.8% |
8/11/2026
Event 6/30/2026
|
||||
| 5AM Partners VII, LLC | 7.8% | |||||
| 5AM Ventures VII, L.P. | 7.8% | |||||
| Kush Parmar | 7.8% | |||||
| Andrew J. Schwab | 7.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.